Bibhuti Bhusan Kakoti

Bibhuti Bhusan Kakoti

Auto-generated profile, based on publicly available information

Bibhuti Bhusan Kakoti

Department of Pharmaceutical Sciences, Faculty of Science and Engineering, Dibrugarh University, Dibrugarh, India

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2005 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
MGM. Gupta
M. Gupta
UMU.K. Mazumder
U.K. Mazumder
RKR. Sambath Kumar
R. Sambath Kumar
PGP. Gomathi
P. Gomathi
YRY. Rajeshwar
Y. Rajeshwar
VSV. Tamil Selven
V. Tamil Selven

13 February 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
Vivek P. ChavdaVivek P. Chavda
Vivek P. Chavda
RBRajashri Bezbaruah
Rajashri Bezbaruah
DVDisha Valu
Disha Valu
BPBindra Patel
Bindra Patel
AKAnup Kumar
Anup Kumar
MJMariya Jesawadawala
Mariya Jesawadawala
The coronavirus disease (COVID-19) breakout had an unimaginable worldwide effect in the 21st century, claiming millions of lives and putting a huge burden on the global economy. The potential developments in vaccine technologies following the determination of the genetic sequence of SARS-CoV-2 and the increasing global efforts to bring potential vaccines and therapeutics into the market for emergency use have provided a small bright spot to this tragic event. Several intriguing vaccine candidates have been developed using recombinant technology, genetic engineering, and other vaccine development technologies. In the last decade, a vast amount of the vaccine development process has diversified towards the usage of viral vector-based vaccines. The immune response elicited by such vaccines is comparatively higher than other approved vaccine candidates that require a booster dose to provide sufficient immune protection. The non-replicating adenoviral vectors are promising vaccine carriers for infectious diseases due to better yield, cGMP-friendly manufacturing processes, safety, better efficacy, manageable shipping, and storage procedures. As of April 2022, the WHO has approved a total of 10 vaccines around the world for COVID-19 (33 vaccines approved by at least one country), among which three candidates are adenoviral vector-based vaccines. This review sheds light on the developmental summary of all the adenoviral vector-based vaccines that are under emergency use authorization (EUA) or in the different stages of development for COVID-19 management.

3 October 2022 in Frontiers in Pharmacology
Verified
Journal Article
Open access
BKBibhuti Bhusan Kakoti
Bibhuti Bhusan Kakoti
RBRajashri Bezbaruah
Rajashri Bezbaruah
NANasima Ahmed
Nasima Ahmed
Drug repositioning or repurposing is the process of discovering leading-edge indications for authorized or declined/abandoned molecules for use in different diseases. This approach revitalizes the traditional drug discovery method by revealing new therapeutic applications for existing drugs. There are numerous studies available that highlight the triumph of several drugs as repurposed therapeutics. For example, sildenafil to aspirin, thalidomide to adalimumab, and so on. Millions of people worldwide are affected by neurodegenerative diseases. According to a 2021 report, the Alzheimer’s disease Association estimates that 6.2 million Americans are detected with Alzheimer’s disease. By 2030, approximately 1.2 million people in the United States possibly acquire Parkinson’s disease. Drugs that act on a single molecular target benefit people suffering from neurodegenerative diseases. Current pharmacological approaches, on the other hand, are constrained in their capacity to unquestionably alter the course of the disease and provide patients with inadequate and momentary benefits. Drug repositioning–based approaches appear to be very pertinent, expense- and time-reducing strategies for the enhancement of medicinal opportunities for such diseases in the current era. Kinase inhibitors, for example, which were developed for various oncology indications, demonstrated significant neuroprotective effects in neurodegenerative diseases. This review expounds on the classical and recent examples of drug repositioning at various stages of drug development, with a special focus on neurodegenerative disorders and the aspects of threats and issues viz. the regulatory, scientific, and economic aspects.

11 June 2021 in Molbank
Verified
Journal Article
Open access
PDF file
NHNazim Hussain
Nazim Hussain
BKBibhuti Bhushan Kakoti
Bibhuti Bhushan Kakoti
Mithun RudrapalMithun Rudrapal
Mithun Rudrapal
KSKhomendra Kumar Sarwa
Khomendra Kumar Sarwa
ICIsmail Celik
Ismail Celik
SWSanjay G. Walode
Sanjay G. Walode
Cordia dichotoma Forst. (F. Boraginaceae) has been traditionally used for the management of a variety of human ailments. In our earlier work, the antidiabetic activity of methanolic bark extract of C. dichotoma (MECD) has been reported. In this paper, two flavonoid molecules were isolated (by column chromatography) and identified (by IR, NMR and mass spectroscopy/spectrometry) from the MECD with an aim to investigate their antidiabetic effectiveness. Molecular docking and ADMET studies were carried out using AutoDock Vina software and Swiss ADME online tool, respectively. The isolated flavonoids were identified as 3,5,7,3′,4′-tetrahydroxy-4-methoxyflavone-3-O-l-rhamnopyranoside and 5,7,3′-trihydroxy-4-methoxyflavone-7-O-l-rhamnopyranoside (quercitrin). Docking and ADMET studies revealed the promising binding affinity of flavonoid molecules for human lysosomal α-glucosidase and human pancreatic α-amylase with acceptable ADMET properties. Based on computational studies, our study reports the antidiabetic potential of the isolated flavonoids with predictive pharmacokinetics profile.

29 July 2013 in BioMed Research International
Verified
Journal Article
Open access
PDF file
BKBibhuti Bhusan Kakoti
Bibhuti Bhusan Kakoti
PPParesh Pradhan
Paresh Pradhan
SBSudarshana Borah
Sudarshana Borah
KMKabita Mahato
Kabita Mahato
MKMritunjay Kumar
Mritunjay Kumar
Stem bark ofNyctanthes arbor-tristisLinn. was extracted in methanol to evaluate their analgesic and anti-inflammatory activities. The analgesic activity was determined on Wistar albino rats by hot plate method, tail flick assay, and tail immersion method using Morphine sulphate as standard drug at a dose of 5 mg/kg of body weight and the results were expressed as mean increase in latency after drug administration ± SEM. The anti-inflammatory activity was assessed by Carrageenan-induced rat paw oedema using diclofenac sodium as standard drug at a dose of 100 mg/kg of body weight and expressed in terms of mean increase in paw volume ± SEM. Stem bark extract was given at a dose of 250 mg/kg and 500 mg/kg of body weight. Both standard drugs and extract were administered orally to the animals. Control received distilled water orally. Results showed thatNyctanthes arbor-tristisLinn. had potent analgesic and anti-inflammatory activities.

21 January 2020 in Current Diabetes Reviews
Verified
Journal Article
Closed access
PDF file
ASAnshul Shakya
Anshul Shakya
SCSUSHIL KUMAR CHAUDHARY
SUSHIL KUMAR CHAUDHARY
DGDebapriya Garabadu
Debapriya Garabadu
HBHans Raj Bhat
Hans Raj Bhat
BKBibhuti Bhusan Kakoti
Bibhuti Bhusan Kakoti
SGSurajit Kumar Ghosh
Surajit Kumar Ghosh
Background: Preclinical experimental models historically play a critical role in the exploration and characterization of disease pathophysiology. Further, these in-vivo and in-vitro preclinical experiments help in target identification, evaluation of novel therapeutic agents and validation of treatments. Introduction: Diabetes mellitus (DM) is a multifaceted metabolic disorder of multidimensional aetiologies with the cardinal feature of chronic hyperglycemia. To avoid or minimize late complications of diabetes and related costs, primary prevention and early treatment are therefore necessary. Due to its chronic manifestations, new treatment strategies need to be developed, because of the limited effectiveness of the current therapies. Methods: The study included electronic databases such as Pubmed, Web of Science and Scopus. The datasets were searched for entries of studies up to June, 2018. Results: A large number of in-vivo and in-vitro models have been presented for evaluating the mechanism of anti-hyperglycaemic effect of drugs in hormone-, chemically-, pathogen-induced animal models of diabetes mellitus. The advantages and limitations of each model have also been addressed in this review. Conclusion: This review encompasses the wide pathophysiological and molecular mechanisms associated with diabetes, particularly focusing on the challenges associated with the evaluation and predictive validation of these models as ideal animal models for preclinical assessments and discovering new drugs and therapeutic agents for translational application in humans. This review may further contribute to discover a novel drug to treat diabetes more efficaciously with minimum or no side effects. Furthermore, it also highlights ongoing research and considers the future perspectives in the field of diabetes.